The company expects 2017 revenues to range from $3.45 billion to $3.60 billion, and adjusted EBITDA from $1.50 billion to $1.58 billion.
In fiscal 2016, the company's net loss per share was $14.48, adjusted earnings per share were $4.66, and revenues were $4.01 billion.
In its fourth quarter, net loss attributable to the company was $3.34 billion or $14.98 per share, compared to loss of $118.46 million or $0.53 per share last year.
The latest results included $3.5 billion of asset impairment charges associated with the write-down of goodwill and intangible assets primarily related to the Company's Generics reporting unit.
Adjusted earnings per share from continuing operations were $1.77. Total revenues were $1.24 billion, higher than $1.07 billion last year.
Further, the company announced the divestiture of Litha Healthcare Group to Acino for approximately $100 million.
As part of Endo's strategic assessment and comprehensive asset review, Litha no longer aligned with its strategy and was not considered a core asset. ■
What to read next
More inside POST
Südzucker FY16/17 profit surges Earnings